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ABSTRACT 
The prediction of binding poses and affinities is an area of active interest in computer-aided drug 
design (CADD). Given the documented limitations with either ligand or structure based 
approaches, we employed an integrated approach and developed a rapid protocol for binding 
mode and affinity predictions. This workflow was applied to the three protein targets of 
Community Structure–Activity Resource-2014 (CSAR-2014) exercise: Factor Xa (FXa), Spleen 
Tyrosine Kinase (SYK) and tRNA (guanine-N(1)-)-methyltransferase (TrmD). Our docking and 
scoring workflow incorporates compound clustering and ligand and protein structure based 
pharmacophore modeling, followed by local docking, minimization and scoring. While the 
former part of the protocol ensures high-quality ligand alignments and mapping, the subsequent 
minimization and scoring provides the predicted binding modes and affinities. We made blind 
predictions of docking pose for one, five and 14 ligands docked into one, two and 12 crystal 
structures of FXa, SYK and TrmD, respectively. The resulting 174 poses were compared with 
co-crystalized structures (one, five and 14 complexes) made available at the end of CSAR. Our 
predicted poses were related to the experimentally determined structures with a mean root mean 
square deviation value of 3.4Å. Further, we were able to classify high and low affinity ligands 
with the area under the curve values of 0.47, 0.60 and 0.69 for FXa, SYK and TrmD, 
respectively, indicating the validity of our approach in at least two of the three systems. Detailed 
critical analysis of the results and CSAR methodology ranking procedures suggested that a 
straightforward application of our workflow has limitations, as some of the performance 
measures do not reflect the actual utility of pose and affinity predictions in the biological context 
of individual systems.  
  
INTRODUCTION 
The stated goal of the CSAR-2014 exercise is the evaluation of various computer aided drug 
design (CADD) techniques for pose and affinity prediction. The range of CADD techniques are 
broadly classified into ligand based drug design (LBDD) and structure based drug design 
(SBDD) approaches
1
. LBDD approaches are generally applicable to targets with no three-
dimensional (3D) structures, are quicker and better interpretable to chemists. Prototypical ligand 
based approaches such as (3D) Quantitative Structure-Activity Relationships (QSAR) models or 
pharmacophore based models use physicochemical properties and conformational preferences 
for explaining the variation in structure-activity relationships (SARs). However, ligand based 
approaches can only be used when a sufficient amount of activity data are available and their 
utility for pose prediction depends on the availability of the bioactive conformations of one or 
more active compounds. Furthermore, selecting a model that reflects the biochemical reality is a 
difficult issue, as selection criteria that use statistical significance alone might lead to erroneous 
model prioritization from a pool of possible models.
2
 On the other hand, SBDD can be used for 
making de novo predictions and for designing, more rationally, compounds that could interact 
with selected motifs in the protein’s active site.
3, 4
 However, this approach, suffers from huge 
computational costs, the uncertainties of the scoring functions and the problem of binding pose 
selection. 
1,3-6,7
 Previous CSAR contests have shown that while SBDD can reproduce ligand 
binding pose within 2Å, it fails to accurately rank order ligands by affinity.
5
 In some instances 
(such as Urikinase) SBDD was able to classify active ligands from inactives.
5
 In general, 
however, SBDD approaches failed to identify “activity cliffs”, which a ligand based approach 
(such as QSAR) might be able to explain by analyzing the conformational preferences or 
physicochemical properties such as pKa, where a single log order change can produce several 
orders of magnitude variation in activities.
8, 9
 In view of the above, we propose an integrated 
structure and ligand based approach employing a structure-based pharmacophore to address the 
limitations and provide a rapid protocol for binding mode and affinity predictions. The workflow 
is also computationally scalable for the virtual screening of large chemical libraries. 
In this paper, we report the results of our protocol applied to the three CSAR-2014 datasets in the 
following sections: (1) Integrated protocol for predicting binding poses and affinities, (2) Cluster 
analysis of target chemical space, (3) Structure, active site and structural integrity of functional 
motifs,  (4) Protein structure based pharmacophore,  (5) Blinded docking pose and affinity 
predictions, (6) Visual inspection of the binding modes of representative CSAR-2014 ligands 
and (7) The minimum requirements and applicability domain of the protocol. 
RESULTS AND DISCUSSION 
(1)  Integrated protocol for predicting binding poses and affinities: 
As discussed in Introduction, the application of ligand or structure based approaches alone 
presents significant challenges for pose and affinity prediction.
1
 Hence, we developed a 
workflow illustrated in Figure 1, which encompasses a) cluster analysis of the target chemical 
space, b) conformation generation, c) ligand and protein structure-based pharmacophore 
generation and mapping (pose prediction) and d) subsequent minimization and scoring (affinity 
prediction). This workflow addresses the difficulties in: 1) the selection of pharmacophore 
models, which capture known essential interactions, 2) the automatic selection of docking poses 
and 3) the computational scalability. The calibration of the scoring function remains an 
unresolved issue and thus, the predicted affinity values may have to be interpreted with caution. 
Below, we will describe these workflow elements in more detail.  
(2) Cluster analysis of target chemical space 
Our workflow starts with the construction of the target chemical space, i.e., a collection of all the 
chemical compounds known to interact with a given target and their associated properties. 
Cluster analysis helps us identify representative compounds for the generation of 
pharmacophores and also further assess visually the binding modes and affinities of selected 
representative drugs and tool compounds. For this part of the study, we employed Weighted 
Gene Coexpression Network Analysis (WGCNA),
10
 an advanced unsupervised machine learning 
method with elements similar to cluster analysis.
10
 In contrast to most cluster analysis methods, 
WGCNA offers several unique features including a) topological overlap measure (TOM) as a 
proximity indicator to identify modules, b) tuning the soft thresholding parameter beta such that 
approximate scale free topology is reached and c) a fuzzy clustering method.
11
 Hard-thresholding 
(rigid similarity cut-off such as 0.7) in cluster analysis has been a significant issue in chemical 
similarity analysis and often led to unreliable or subjective classification of chemical structures.
12
  
In addition, among the available range of clustering methods, network based methods are 
considered to be the best (accurate and reproducible) hence WGCNA was used to cluster 
compounds. WGCNA can furthermore relate clusters to external attributes such as chemical 
scaffolds to assess the similarity content of the modules derived using various cluster 
thresholding parameters. 
Scaffolds are one of the major chemical space attributes and constitute the functionally important 
building blocks of chemical structures.
13,14, 15
 They have a strong influence on pharmacodynamic 
and pharmacokinetic profiles. Hence we analyzed the scaffold composition of the various 





 SNG is an open-source command-line utility that computes the 
hierarchical network of scaffolds that define a large set of input molecules, while molBLOCKS 
is a suite of programs for breaking down sets of small molecules into fragments according to a 
predefined set of chemical rules, clustering the resulting fragments, and uncovering statistically 
enriched fragments. 
Determining the number of clusters in a data set is a frequent problem in data clustering. In the 
present study, we applied a method analogous to the ‘the elbow method’ and visually inspected 
the relationship between the number of clusters and the total number of enriched scaffolds 
(Supporting information.2 tables S10-S12; see Materials and Methods for more details) and also 
examined the consistency between the cluster assignments and known chemical classification. 
The optimal thresholding cutoffs thus chosen resulted in 279, 71 and 322 clusters for the Fxa, 
SYK and TrmD global chemical spaces, respectively. 
(3) Structure, active site and structural integrity of functional motifs 
To prioritize the structure based pharmacophores that reflect the biological reality and are 
applicable to the global chemical space of the targets, understanding the functional motifs is 
critical.
18
 Furthermore, since CSAR-2014 experimental data constitute the functional IC50 (half 
maximal inhibitory concentration) values, the structural integrity of the functional motifs is 
critically important for the application of our integrated LBDD and SBDD protocol for a 
reasonable activity prediction.
19
 Hence we began by analyzing the structure, active site and 
structural integrity of functional motifs in comparison to prototypical crystal structures. A 
“prototypical” crystal structure of a target is a structure where all the major functional motifs and 
important secondary structure elements are intact.
19-21
  Prototypical structures are often co-
crystallized with natural substrates, as these studies are aimed at elucidating the structure-
function mechanisms of the target proteins. Although in the present study, we visually inspected 
for the conservation of the functional motifs, this process of selecting the prototypical structures 
could be automated using methods such as ‘RINerator’.
22
 
In addition, functional motifs in proteins contribute to their structure, and to the specificity of 
their interactions with other biomolecules including cognate ligands. They are often conserved 
across the broader superfamily and also constitute “hot spots” that can form strong interactions 
with ligands.
23
 Site directed mutagenesis experiments furthermore indicate the crucial role of 
these in structure-function modulation of proteins.
24
 Thus it is vitally important to review 
functional motifs and asses their structural integrity for a proper evaluation of pose and affinity 
predictions. 
(3.1) Functional motifs and structural integrity of FXa 
Factor Xa contains a serine protease domain in a trypsin-like closed two β-barrel fold 
encompassing the catalytic triad Ser195-His57-Asp102, two essential sub-sites S1 and S4, two 
disulphide bridges and an autolysis loop (table 1).
25, 26
 The prototypical crystal structure (PDB ID, 
1FAX) revealed a set of key motifs, including the S4 pocket that contains Aromatic box and 
cation hole.
 2
 The structural integrity of the S1 and S4 pockets is critical for the accurate 
prediction of the binding modes of FXa compounds. Among the three crystal structures provided 
in CSAR-2014, ‘FXa_gtc000401_2.07.pdb’ seemed the closest to the prototypical structure (in 
particular, the conserved autolysis loop) and hence was used for docking (Supporting 
information.2 figure S1). However, even this structure displays no cationic hole, with the side 
chain of Glu97 pointing away from the binding site. The other critical S1 pocket, too, is partially 
intact, with the Gln192 residue pointing away from the ligand binding site (Supporting 
information.1 figure S1). These structural variations could introduce significant challenges in 
predicting the binding modes, especially of non-aromatic P4 fragments. 
(3.2) Functional motifs and structural integrity of SYK 
The prototypical crystal structures of active SYK (PDB ID, 4FL1 and 1F6E) revealed a set of 
key residues (table 2 and Supporting information.2 figures S2 and S3).
 27
The structural integrity 
of the catalytic site, the gate keeper residue (in hydrophobic pocket 2) and the p-loop (also 
known as the glycine rich loop) are critical for the accurate prediction of the binding modes of 
SYK compounds. Among the eight crystal structures provided by CSAR-2014, 
‘SYK_GTC000224.pdb’ and ‘SYK_GTC000249.pdb’ seemed the closest to the prototypical 
structures and hence were used for docking. The SYK kinase domain of these two structures has 
a subdomain structure typical of other kinases, with a largely β-sheet N-terminal lobe, a largely 
α-helical C-terminal lobe, and the active site sandwiched between the two lobes. The N-terminal 
lobe consists of a five-stranded β-sheet plus a single α-helix equivalent to the C-helix of PKA. 
The larger C-terminal lobe is predominantly α-helical with three short β-strands: one at the hinge 
region and two between the activation loop and the main body of the C-lobe.  
However, even these two structures display little structural integrity at the catalytic pocket, 
with the side chain of Lys402 pointing away from the binding site and no salt bridge interaction 
between the Lys402 and Asp512, which is required for the catalytic action of the kinase 
(Supporting information.2 figures S3 and S4). The other critical element, p-loop, though, is intact 
in ‘gtc000249_SYK.pdb’ but is completely missing in ‘gtc000224.pdb’ (Supporting 
information.2 figure S4). The flexible p-loop constitutes one of the major structure-function 
motifs of the ATP competitive inhibitors. It serves to close the gap between the N- and C-lobes 
thereby enabling the stabilization of the kinase in the inactive conformation in which ATP cannot 
bind. We will discuss the implications of these structural variations for predicting the binding 
modes and affinities in the subsequent sections. 
(3.3) Functional motifs of TrmD  
TrmD has a homodimeric structure with 29.7kDa per protomer.
28
 The AdoMet binding site is 
located between the dimeric interfaces and forms a characteristic deep trefoil knot at the N-
terminus. The AdoMet binding site forces the cofactor into a bent “L” conformation on binding. 
Most of the prokaryotic methyl transferaces (TrmDs) are classified as Type 1 tRNA 
methyltransferase.
29
 They do not require the tertiary structure of tRNA for their enzymatic 
action.
29
 The prototypical crystal structural of TrmD (Protein Data Bank ID 1P9P) revealed a key 
set of motifs (Table 3), which were observed in all the TrmD crystal structures submitted in 
CSAR-2014 competition. 
 
 (4) Protein structure based pharmacophore 
A pharmacophore describes the arrangement of molecular features that a ligand must contain to 
efficaciously bind a receptor.
30-33
 Pharmacophore models are of two kinds, ligand based and 
protein structure-based. The former are derived using representative ligands in their bioactive 
conformation and the later are derived using molecular features by conversion of protein 
properties to reciprocal ligand space. In the present work, we derived an integrated 
pharmacophore model using the active site conformations of the representative compounds 
(selected by the WGCNA cluster analysis) co-crystalized with each target (figure 2). This model 
was initially generated as a ligand based model (using the PharmaGist software) and 
subsequently improved by adding excluded volumes, a feature of a protein structure based model 
(using the Pharmer software). The three protein structure based pharmacophores used for 
generating the docking poses and affinities are described below. 
  (4.1) FXa 
Essentially, the FXa structure based pharmacophore (figure 2b) captures a) the pi- and hydrogen 
bonding interactions of ‘6-chloronaphthalene’ with FXa’s S1 pocket (Tyr228, Asp189, Ala190, 
Ser214) (labeled RingAromatic and Acceptor), b) the hydrogen bond acceptor interactions 
(labeled Acceptor and Acceptor) of the 2-sulfonamido group with Gln192, another critical 
residue of the S1 pocket, c) the hydrogen bond acceptor interactions (labeled Acceptor) of 
pyrrolidin-2-one and finally d) the interactions 1-methyl-1,4-diazepane terminal amines with the 
residues of S4 cationic hole (labeled Ionizable_Positive) as a positive ionizable feature.   
(4.2) SYK 
The SYK structure based pharmacophore  (figure 2d) captures a) the hydrogen donor and 
acceptor interactions of the hinge binding fragments with Ala451 and Glu452 (labeled Donor 
and Acceptor, respectively), b) the hydrophobic interactions of the hinge binding fragments with 
Met450 (labeled RingAromatic), c) cation pi-interactions of the catalytic site binding fragments 
with Lys402 (labeled RingAromatic), d) the hydrogen bond donor interactions of the catalytic 
site binding fragments with Glu420 from the C-helix (labeled Donor) and e) the hydrogen bond 
acceptor interactions of the hydrophobic pocket 1 fragments with Gly378 of the p-loop (labeled 
acceptor). 
(4.3) TrmD 
Figures 2f illustrates the features of our TrmD pharmacophore models mapped to 
‘GTC000448A’ co-crystallized with ‘TRMD_448.pdb’. Essentially, the TRMD pharmacophore 
model is a mirror image of the interaction diagram of ‘GTC000448A’ with its cognate protein 
TRMD_448.pdb’ (figure 2e). 
 
(5) Blinded docking pose and affinity predictions 
To create the docked structures, we minimized pharmacophore mapped conformations within the 
protein active sites to remove unfavorable contacts with the protein and relax the ligand 
conformations. The quantitative performance of the docked poses and affinity predictions was 
performed using the root mean square deviation (RMSD) and an analysis of the area under the 
curve (AUC) of the receiver operator characteristic (ROC) curves respectively. 
(5.1) Blinded docking pose prediction- quantitative assessment using RMSD values.  
The CSAR-2014 organizers provided the participants with multiple crystal structures (Table 4) 
for each of the three targets and blinded pose predictions were assessed for one FXa, five SYK 
and 14 TrmD ligands, respectively. As part of our analysis, we docked 163 FXa ligand structures 
into one FXa crystal structure ‘fxa_gtc000401_2.07.pdb’ and the RMSD value was calculated for 
the ligand used in the blinded docking assessment, ‘GTC000101A’. Similarly for SYK we 
docked 272 SYK inhibitors into two SYK crystal structures, ‘gtc000224_SYK.pdb’ and 
‘gtc000249_SYK.pdb’ using two structure based pharmacophore models. However, the RMSD 
values were estimated for the five SYK compounds docked into ‘gtc000249_SYK.pdb’ only. 
Thus we present the mean and median of these five RMSD values. Finally, we docked 31 TrmD 
ligands into the 14 crystal structures using 14 different structure based pharmacophore models. 
The blinded pose predictions were assessed for 14 of the 31 ligands docked into 12 of the 14 
target structures resulting in 168 (= 14 × 12) RMSD values for TrmD. Thus, the total number of 
poses for which the RMSD was calculated based on our participation was 174 (= 1 + 5 + 168).   
The overall mean value of 3.5 Å across 174 predicted poses suggests that protein structure 
based pharmacophores for pose prediction should be used with caution. The median and mean 
RMSD values of one FXa (6.03 Å and 6.03 Å) and five SYK (4.28 Å and 4.01 Å) inhibitors 
predicted by our method were comparatively higher than all the participants’ median and mean 
values for FXa (2.94 Å and 2.98 Å) and SYK (2.58 Å and 2.46 Å) (table 4, figure 3). From 
the visual analysis of representative compounds of all three targets (presented in the next section), 
it is clear that most of the representative compounds’ binding modes were reasonably close to the 
expected protein-ligand contacts. Though our protocol worked reasonably well in mapping the 
compounds to the structure based pharmacophores described above, the subsequent minimization 
with SMINA led to significant deviations; for instance ‘GTC000101A’ the FXa compound used 
in the blinded docking study deviated by 6.03 Å after minimization with SMINA (figures 3a 
and 3b). The low predicted score of ‘3.6044’ also indicates the minimization did not reach 
convergence. The lack of adequate conformational sampling or even the solvent-exposed binding 
pocket of the FXa and absence of sufficient number of anchor residues or functional motifs such 
as the cation hole could also have contributed to the unusually large RMSD value of 
‘GTC000101A’.  
The significant variation between the predicted and experimental structures for ‘gtc000224’ 
docked with ‘gtc000224_SYK.pdb’ can primarily be attributed to the ‘1,3‐oxazol‐5‐yl’ 
fragment, which binds in the solvent-exposed region that is located outside the hinge pocket and 
adjacent to the ribose pocket. In addition, the flexible aminopropan-1-ol fragment of ‘gtc000224’ 
also deviated significantly between the predicted and experimental poses and hence produced an 
overall RMSD value of 3.49 Å (figures 3c and 3d). The difficulties in predicting the binding 
modes of fragments at solvent exposed pockets were widely discussed in the literature. 
The pose predictions for TrmD with median and mean RMSD values of 3.20 Å and 2.53 Å 
across 168 predicted poses were comparatively better than the overall median and mean RMSD 
values (3.84 Å and 3.52 Å) obtained by all the participants of this contest. This result could 
primarily be attributed to the buried polar binding pocket of TrmD. However, a major difference 
between the experimentally determined and predicted structures of GTC000448A is the result of 
an alternative overlay of oxadiazol-3-amine fragment, which resulted in an RMSD of 4.57 Å 
(figures 3e and 3f). This observation highlights a major issue with protein-structure based 
pharmacophores for pose predictions, where alternative alignments are possible and hence 
requiring manual inspection or an extended workflow to include protein-ligand fingerprint 
analysis. Appropriate tutomeric and protonation state assignments can also greatly reduce the 
possibility of such alternative docking poses.  
(5.2) Blinded docking rank ordering and classification of actives versus inactivies 
Although our approach can be described as an integrated approach, it is essentially a crude 
docking method and hence primarily an SBDD approach.  While conventional docking approach 
starts by generating grid potential maps for the protein and ligand and using them to 
complementarily place the ligands within the protein pockets, the structure based pharmacophore 
approach uses predefined pharmacophoric features as constrains to dock ligands. As expected 
with a SBDD protocol, no statistically significant correlation was observed between 
experimental IC50 and predicted activity values with R2 values of 0.001, 0.013 and 0.164 for 
FXa, SYK and TrmD, respectively (table 5). The poor correlation values of our approach could 
also be the result of the least squares based measures being less robust with respect to outliers. 
Our rapid and crude docking workflow together with inadequate conformational sampling also 
produced a large number of outliers, mostly as a result of the SMINA minimized poses, which 
did not converge to an energy minimum. In some instances the pharmacophore-predicted pose 
was stuck due to an unfavorable clash with the protein or due to an alternative alignment picked 
by the pharmacophore. Hence we decided to use the area under the curve (AUC) of receiver 
operator characteristic (ROC) curve values to quantitatively assess the classification accuracy of 
the predicted affinities. Furthermore the AUC measures from ROC curves are generally 
considered to be more robust with respect to outliers and hence can be considered better 
measures for quantitative assessment. The measured AUC values of all compounds predicted in 
the competition and the compounds of the individual clusters are presented in tables 6 and 7. In 
spite of the relatively poor correlation between the experimental and predicted affinities, our 
protein structure based approach discriminated active from inactive compounds reasonably well 
for at least two targets, as demonstrated by the AUC values of 0.47, 0.60 and 0.69 for FXa, SYK 
and TrmD, respectively (where the actives were defined as the compounds with pIC50 > 7.5 for 
FXa and SYK and with pIC50 > 5.5 for TrmD) (figure 4). Since we varied the “cutoff” values 
and had multiple structures to choose from for the SYK and TrmD systems, the AUC values of 
0.60 and 0.69 for SYK and TrmD may have a level of overfitting and caution needs to be 
exercised in interpreting these results. For FXa and SYK, we choose a cut-off of ‘7.5’, since this 
cut-off afforded relatively equal numbers of actives and inactives in comparison to other cut-offs 
(table 6). For TrmD, the cut-off that afforded relatively equal numbers of actives and inactives 
was 5.5. In addition, among the two crystal structures of SYK that we used for docking, we 
chose ‘gtc000224_SYK‘, as this crystal structure had a better structural integrity of active site 
motifs, Among the several high scoring TrmD crystal structures, we chose TrmD_448 for the 
ROC curve depiction, as its co-crystalized ligand was representative of the TrmD ligand set.  
Some of the additional insights that can be gained from tables 6 and 7 include the identification 
of outlier clusters such as ‘deeppink’ FXa cluster (AUC=0.18) and ‘royalblue’SYK cluster 
(AUC=0.17).  
(6) Visual inspection of the binding modes of representative CSAR-2014 ligands 
The assessment of pose prediction is typically performed using quantitative measures such as 
RMSD or can be visually inspected for native contacts with selected critical residues implicated 
in the structure function mechanisms of the proteins. Previous CSAR exercises have highlighted 
the issues with RMSD and the need for multiple approaches to assess the performance of 
docking poses. The notable issues include the unreliability of RMSD values in a flexible docking 
protocol, the artificially low RMSD values of small molecules and high RMSD values of 
symmetric molecules.
5
 In addition, docking typically fails to identify native poses in solvent 
exposed and flexible pockets such as the S2-S3 pockets in FXa and the p-loop pocket in SYK. 
Hence, a visual inspection of the binding modes of representative members of clusters of FXa, 
SYK and TrmD could throw further light on the general quality of docking and the conservation 
rate for ligand-residue contacts. 
(6.1) FXa 
Both the predicted poses of various FXa inhibitors and the crystal structures of potent inhibitors 
in complex with FXa (figures 3a and 3b, supporting information.2 tables S13 to S16) revealed 
that the inhibitors adopt L-shaped binding conformations with two major anchoring points at S1 
and S4 sites. 
In the present study, we analyzed the binding modes and enriched fragments of CSAR-2104 FXa 
compounds comprehensively in relation to the global FXa chemical space. Such an analysis 
should help us infer the novelty in the CSAR-2104 FXa chemotypes, the difficulties in predicting 
the binding modes, and the physicochemical property profiles in comparison to well-studied FXa 
drugs and tool compounds. 
In general, our protocol, despite poorly classifying the experimental activities of the FXa dataset 
(overall AUC= 0.47), reproduced expected binding modes of CSAR-2014 representative FXa 
ligands reasonably well (Supporting information.2 tables S13 to S15). In particular, most 
compounds faithfully reproduced the expected binding modes at the S1 pocket, where the 
halogen atom of naphthalene or thiophene moiety maintains hydrogen bond acceptor and T-
shaped pi staking interactions with the S1 pocket residues (Supporting information.2 tables S13 
to S15). In addition, our protocol was able to process the 163 compounds in several CPU minutes 
(compared to several CPU hours by typical docking packages) and thus it is computationally 
scalable for larger datasets. This way, it significantly reduced the efforts needed for post docking 
processing and analysis, which is typically performed manually and involves visual inspection. 
However, given the limited accuracy of the protein structure based pharmacophore in predicting 
the FXa inhibitor binding modes and affinities in the blinded docking study, our workflow has to 
be used with caution. 
Since the cation hole in the S4 pocket is not intact in any of the structures provided by the 
CSAR-2014 organizers, the binding mode predictions for this site deviated from the expected 
trend. The co-crystallized ligand structure of ‘FXa_gtc000401_2.07.pdb’ also failed to interact 
with the sidechain or the backbone atoms of Glu97 and the observed conformation of the P4 
fragment could be an artifact of crystal packing (figures 2a and 2b). Our pharmacophore model 
included features such as positive ionizable and may guide the P4 fragments into the S4 pocket. 
However, many docked poses (in particular ‘darkorchid4’ and ‘coral3’ modules) deviated from 
the expected placement of the P4 fragments, since our protocol also involved minimizing the 
ligand in the active site and found no anchor for the non-aromatic P4 fragments to engage with 
the S4 pocket (which contains both cation hole and the aromatic box in the prototypical 
structure). The ‘tan’ and ‘darkorchid4’ modules performed the worst in terms of predicting both 
the binding mode and binding affinities of the representative compound. Several reasons could 
be attributed; (1) adequate conformational sampling of FXa ligands was not performed, (2) the 
lack of structural integrity of the S4 and S1 motifs and (3) the conformational preferences of the 
compounds, which manifested during the SMINA minimization steps. 
Furthermore, in contrast to natural substrate/inhibitor binding geometries, as well as the vast 
majority of synthetic inhibitor complexes with serine proteinases,
45
 many compounds  
(GTC000051A_set3, GTC000047A_set2, GTC000104A_set3, GTC000075A_set3, 
GTC000101A_set2, GTC000091A_set3, GTC000103A_set3, B22617, and B50848802) formed 
no hydrogen bond with Gly-216. This can also be observed in the protein ligand interaction 
profiles of PDB IDs 1EZQ and 2P93 and explains the considerable variation of the P2 and P3 
fragments in FXa inhibitor design. Thus, the geometric restraints of binding in the S1 and aryl-
binding S4 pockets have allowed considerable variation of the P3 fragments in inhibitor design. 
The co-crystallized and predicted binding modes of the compounds described demonstrate the 
feasibility of ignoring hydrogen bonding at Gly-216 and point to the existence of several possible 
alternative binding modes of the P3 fragments in particular and other fragments in general.
34
 
The WGCNA cluster analysis and subsequent scaffold enrichment analysis revealed that ‘N-(2-
oxo-1-phenylpyrrolidin-3-yl)-2-(thiophen-2-yl)ethene-1-sulfonamide’ is a common scaffold 
across most of the CSAR-2014 FXa modules, except for the ‘brown4’ module, which contains 
the ‘N-thiophene-2-sulfonamide’ as the common scaffold. 
The homogeneity in chemical clusters can also be verified by structural similarity between the 
representative compound of each module and the enriched fragment or scaffold (Tables S13- 
S16). The compounds and their attributes (including physicochemical properties) of all the 
modules, the enriched scaffolds and the statically enriched scaffolds are described in supporting 
information.1 tables S1-S3.   
(6.2) SYK 
Both the predicted poses of various SYK inhibitors and the crystal structures of potent inhibitors 
in complex with SYK (Supporting information.2 tables S17 to S19) revealed that the inhibitors 
adopt flat binding conformations with three major anchoring points at the hinge (Met450, Ala451 
and Glu452), the catalytic pocket (Lys 402, Asp512 and Glu420) and the p-loop (Gly378 and Ser 
379).  
Our protocol reproduced the experimental binding modes for the five newly crystallized 
compounds reasonably well (with an RMSD of around four angstroms) and produced the 
expected binding modes for most of the other compounds. In particular, most compounds 
faithfully produced the expected binding modes at the hinge pocket and the catalytic site 
(Supporting information.2 tables S17 and S18). 
The structural integrity of the two kinases in the CSAR-2014 competition seemed to have little 
influence on the binding modes of the kinase inhibitors, since the inhibitors find additional 
anchors such as Glu420 in the catalytic pocket. However, since the structural integrity of the p-
loop is only partially preserved in ‘SYK_GTC000249.pdb’ and is completely absent in 
‘SYK_GTC000224.pdb’, the predicted binding modes in hydrophobic pocket 1 deviated from 
the existing co-crystal structures. In addition, since this pocket is solvent-exposed, it is generally 
difficult to predict the binding modes accurately without considering solvent effects adequately. 
On the other hand, the lack of structural integrity seems to impact the predicted binding affinities. 
The predicted binding affinities of the CSAR-2014 SYK inhibitors docked to 
‘SYK_GTC000224.pdb’ agreed better with the experimental activities (overall AUC=0.60] 
compared to those docked to ‘SYK_GTC000249.pdb’ (overall AUC=0.44] (tables 7). Since the 
catalytic site is better preserved in ‘SYK_GTC000224.pdb’ than in ‘SYK_GTC000249.pdb’ 
while the p-loop is better preserved in SYK_GTC000249.pdb’ than in ‘SYK_GTC000224.pdb’, 
the catalytic site appears to be more important in predicting the experimentally measured 
inhibitory activities. The predicted activities are presented in supporting information.1 table S4 
to S6 together with the module assignments and enriched fragments and significantly enriched 
fragments. 
(6.3) TrmD 
Both the predicted poses of various TrmD inhibitors and the crystal structures of representative 
inhibitors in complex with TrmD (figures 3e and 3f; supporting information.2 tables S20 and 
S21) revealed that the inhibitors adopt L-shaped binding conformations with two major 
anchoring points at the adenine binding pocket and the ribose site. 
In general, our protocol reasonably reproduced the experimental affinity (AUC = 0.69) and the 
binding modes of the 14 newly co-crystalized compounds (with the mean root mean square 
distance of around 2.53 Å). In particular, most compounds faithfully reproduced the expected 
binding modes at the adenine binding pocket, where a pair of hydrogen bond acceptor and donor 
maintain interactions with the hydroxyl of Ser132 (figures 3e and 3f; supporting information.2 
table S21).  
(7) The minimum requirements and applicability domain of the protocol 
The major strengths and limitations of our structure based pharmacophore approach were 
discussed in the various subsections of 5.1 to 5.3 and 6.1 to 6.3. In the following sections, we 
discuss the minimum requirements and applicability domain of the structure based 
pharmacophore approach for pose and affinity prediction. 
The minimal requirements of our method are broadly akin to those of a typical protein-ligand 
docking study; they include polar and buried active sites of known structure with bound ligands, 
as highlighted in Meslamani et al. (2012)
18
 and Smith et al. (2011).
35
 In addition, our method is 
particularly sensitive to the structural integrity of key motifs, because our structure-based 
pharmacophore approach aims to optimize interactions with these motifs.
36
 The importance of 
structural motifs was highlighted in structure-based drug design of kinases, where the protein 
structures are typically classified into DFG-in, DFG-out, and so on, and appropriate structures 
are chosen for docking type1, type2 and type1.5 inhibitors.
37
 However, in a real life scenario in 
which no such knowledge of structural classification is available, it is possible to use snapshots 
from a molecular dynamics trajectory
19-21
, side chain rotamer exploration or a method such as 
that of Kufareva and Abagyan
38
, who presented a computational protocol (Deletion-Of-Loop 
asp-PHe-gly-IN (DOLPHIN) kinase models) for converting multiple available DFG-in structures 
of various kinases into accurate and specific models of their type-II-bound state. 
Protein-based pharmacophore models are of two kinds: those derived from the protein binding 
atoms and those derived using prior knowledge of active ligands. Our method belongs to the 
latter and is restricted to targets with at-least one co-crystal. Our method is similar in principle to 
Tropsha et al’s CSAR-2013 submission
39
, where protein ligand fingerprints were used to 
discriminate binders from non-binders. Furthermore Koes et al.
7
 reported the application of an 
older version of SMINA for scoring co-crystallized ligands in the CSAR 2012 exercise with 
reported median ranked performance. However, in the present article we report for the first time 
the application of a protein-structure based pharmacophore approach incorporating (1) WGCNA 
clustering, (2) SNG-derived chemical scaffold analysis and (3) a combined protein structure 
based docking tool (Pharmagist + Pharmer + SMINA) for the prediction of binding modes and 
affinities of protein-ligand interactions in the CSAR exercise. 
 
Conclusion 
In the present study, we report the application of an integrated ligand and structure based 
approach to the prediction of binding modes and affinities for FXa, SYK and TrmD inhibitors. 
We highlighted major advantages of this approach such as the derivation of pharmacophore 
models applicable to the global target chemical space, the automated selection of binding modes, 
and computational scalability, together with limitations such as limited sampling rates (due to 
pre-computed conformers). The performance of our protein structure pharmacophore approach 
was affected in part by the SMINA minimization, which often did not converge to a minimum. 
Future work will address these issues. We also highlighted the relevance of structural integrity of 
the S1 and S4 pockets for accurate pose and affinity predictions of FXa compounds, and the 
catalytic site integrity for the pose and affinity predictions of SYK compounds. 
 
Materials and methods 
FXa CSAR-2014 and FXa bindingDB ligand dataset 
The CSAR-2014 FXa dataset consisted of three sets,of pIC50 SAR data points for a total of 163 
compounds with some overlap between the sets. The pIC50 values ranged from ~5 to ~9. This 
dataset was combined with the BindingDB Fxa dataset consisting of 6141 compounds, as 
downloaded from the most recent version of bindingDB. The activity data in bindingDB is 
reported in terms of Ki, Kd and IC50 at nano-molar concentrations. Using an approximation of 
the Cheng-Prusoff equation Ki = IC50/2, the IC50 values were converted to ki values 
(IC50_to_ki).
40
 For consistency, the averages of these three values (ki, kd and IC50_to_ki) were 
converted to log scales. Along with the SAR data, several physicochemical properties and 
scaffolds were computed and presented along with some useful attributes extracted from 
bindingDB (Supporting information.1 tables S1 to S3). 
SYK CSAR-2014 and SYK bindingDB ligand dataset 
The CSAR-2014 SYK dataset consisted of a single set of  pIC50 nM SAR data points for 248 
compounds. The pIC50 values ranged from ~5 to ~9. This dataset was combined with the 
BindingDB SYK dataset consisting of 2500 compounds, as downloaded from the most recent 
version of bindingDB. The activity data in bindingDB were averaged and converted to log scales 
as described above.  Along with the SAR data, several physicochemical properties and scaffolds 
were computed and presented with other useful attributes extracted from bindingDB (Supporting 
information.1 tables S4 to S6). 
TrmD CSAR-2014 and TrmD bindingDB ligand dataset 
The CSAR-2014 TRMD dataset consisted of a set of  pIC50 SAR data points for 31 compounds. 
The pIC50 values ranged from ~4 to ~9. This dataset was combined with the 50 TrmdD ligands 
from AstraZeneca, 6600 anti-Mtb compounds, and 300 antibacterial compounds, along with 600 
random (non-antibacterial) compounds and 350 (non-antibacterial) drugs. (Supporting 
information.1 tables S7 to S9). 
Chemical cluster analysis using WGCNA 
WGCNA, a clustering algorithm that selects clustering cutoffs such that the resulting 
correlation network follows a scale-free distribution,
11
 was used to find sets of structurally 
similar compounds. Using this approach, clusters of compounds with similar structures were 
grouped into modules (labeled by color). Though the WGCNA methodology is typically used for 
studying relationships between gene expression levels,
10
 here we used these techniques for 
studying structural similarities between compounds. WGCNA supports the assembly of both 
unsigned (the Pearson correlation of an unsigned similarity measure is defined as sij
unsigned 
= 
abs(cor(xi,yj), where chemical fingerprint profiles xi and xj consist of the bitvector fingerprints of 
length 4096 for compounds i and j) and unsigned (the Pearson correlation of an unsigned  
similarity measure is defined as sij
signed 
= (1+cor(xi,xj))/2)) networks. 
Since WGCNA was applied for the first time to the cluster analysis of chemoinformatics 
datasets, we also elaborate on two critical aspects of our approach. Firstly, the determination of 
similarity thresholds in chemoinformatics (or in genomics) has been subjective and hence we use 
cluster enrichment analysis for selecting the appropriate thresholding parameters. Cluster 
enrichment analysis is a popular method for comparing the similarity content of different sets 
(either compounds or genes) and calculates enriched entities (such as scaffolds in 
chemoinformatics and gene ontology terms in genomics). In the present study, we used scaffolds 
as entities for enrichment analysis (see below for the definition of scaffolds). Given a set of 
clusters, let ni the number of scaffolds enriched in cluster i compared to all the other clusters 
(with FDR p<0.05 from Fisher’s exact test). We then calculated the total number of enriched 
scaffolds by summing up ni for all the clusters. We examined the relationship between the 
number of clusters and the total number of enriched scaffolds (Supporting information.2 Tables 
S10-S12). Generally, as the number of clusters increased, the total number of enriched scaffolds 
increased up to a point (sometimes known as the “elbow”), where it started to plateau or 
decrease. While the elbow method uses relative variance explained at various cutoffs, we used 
enrichment of chemical scaffolds to identify the optimal number of clusters. 
For FXa and SYK this point was 0.35 for both the unsigned and signed networks. Between the 
unsigned and signed networks, we selected the one, which led to clusters more consistent with 
the known chemical class information as described in the bindingDB entity names. Thus, we 
selected thresholding cutoffs of unsigned_0.35 for Fxa and signed_0.35 for SYK. For TrmD, no 
elbow point was identified and thus, we examined the consistency between the resulting clusters 
and known antibacterial classification and selected a thresholding cutoff of unsigned_0.45. In 
this manner, we aimed to choose the threshold that provided the highest number of enriched 
entities with the least number of clusters.  
Secondly, enriched fragments presented in the current study are essentially the same as chemical 
scaffolds. Fragmentation of chemical structures is often performed using two basic approaches: 
(1) fragmentation using a predefined set of chemical rules and (2) fragmentation using the 
concepts of scaffold tree and scaffold networks. In a typical SAR study, enriched fragments are 
subsequently determined by binning the compounds into active and inactive compounds and 
determining the fragments that map to active in comparison to inactive compounds. However in 
the present study, we performed chemical clustering and scaffold (or enriched fragment) analysis 
to characterize the chemical space; we did not perform structure-function analysis. Enriched 
scaffolds refer to scaffolds enriched in compounds of a given cluster versus compounds of all 
other clusters. Hence our definition of enriched fragments differs from that generally used in the 
literature. 
For FXa, we compiled 6141 compounds from BindingDB, and merged this FXa target chemical 
space with the 163 CSAR-2014 FXa compounds, for which the binding poses and affinities 
should be predicted. The global FXa chemical space (BindingDB + CSAR-2014 FXa chemical 
space) was clustered using WGCNA
10
 with ECFP_12 (extended connectivity fingerprint of 
length 12) fingerprint
17
 (Supporting information.1 table S1).   
In the present study, we explored both signed and unsigned correlation networks derived at 
various merging thresholding parameters (0.0005, 0.005,  0.05, 0.1, 0.25, 0.35, 0.45). Since an 
unsigned network with a merging thresholding parameter of 0.35 presents the least number of 
clusters with the highest number of enriched fragments or scaffolds (Supporting information.2 
table S10), the results with this setting are discussed in this article. Supporting information.1 
table S1 shows the 279 modules (cluster assignment of various compounds) and supporting 
information.1 table S2 shows the results of the SNG’s scaffold enrichment analysis of various 
modules. These modules (clusters) were used to identify representative compounds for 
pharmacophore model generation (see the next section), for assessing the binding mode and 
affinity prediction, and for chemical space analysis (Supporting information.2 tables S13-S16). 
A similar protocol using WGCNA and SNG has implemented for clustering the SYK chemical 
space (Supporting information.1 table S4). The SYK chemical space constitutes the 248 CSAR-
2014 SYK inhibitors and 2182 SYK binding DB compounds. Since a signed network with a 
merging threshold parameter of 0.35 presents the least number of clusters with the highest 
number of enriched fragments or scaffolds (Supporting information.2 table S11), the results with 
this setting are discussed in this article. Supporting information.1 table S4 shows the 71 modules 
(cluster assignment of various compounds) and Supporting information.1 tables S5 and S6 shows 
the results of the SNG’s scaffold enrichment analysis of various modules. These modules 
(clusters) were used to identify representative compounds for pharmacophore model generation 
(see the next section), for assessing the binding mode and affinity prediction, and for chemical 
space analysis (Supporting information.2 tables S17-S19).  
For clustering the TrmD chemical space we first merged 31 TrmD CSAR-2014 ligands with 
33 PubChem derived TrmD ligands together with 7820 antibacterial compounds. Very few 
TrmD chemotypes are reported in the literature and hence we used 7820 antibacterial compounds, 
which also contained 312 antibacterial decoys and 527 human drugs used in previous 
publications. Since an unsigned network with a merging thresholding parameter of 0.45 with the 
ECFP12 fingerprints presented the clustering most consistent with the known antibacterial 
classification (Supporting information.2 table S12), the results with this setting are discussed in 
this article (Supporting information.1 table S7). We initially analyzed the scaffold composition 
of the resulting modules by using SNG but we found no enriched fragments, presumably because 
SNG was unsuitable for diverse and sparse chemical space such as the antibacterial chemical 
space. Hence, we used molBlock (which uses retro-synthetic rules) for deriving scaffolds. 
Supporting information.1 table S7 shows the 322 modules (cluster assignment of various 
compounds) and supporting information.1 tables S8 and S9 shows the results of the molBlock’s 
scaffold enrichment analysis of various modules. These modules (clusters) were used for 
assessing the binding mode and affinity prediction, and for presenting the results of the in silico 
forward chemical space analysis (Supporting information.2 table S21). 
 
Scaffold calculation using SNG and molBlocks 
The input datasets which includes CSAR-2014 Fxa,SYK and TrmD datasets together with the 
bindingDB FXa, SYK and TrmD sets were pre-processed using Discovery studio version 3.5 and 
subsequently submitted to SNG (FXA, SYK and TrmD) and molBlocks (TrmD) for scaffold tree 
and network generation. The output was parsed and used for enrichment analysis using WGCNA. 
The preprocessing steps included assigning bond orders and perceiving aromaticity to 
canonicalize the structures. 
Enrichment analysis 
The WGCNA functions ‘userListEnrichment’
41
 and ‘enrichmentAnalysis’ (of the ‘anRichment’ 
package) were used to measure enrichment between WGCNA derived modules and sets of 
compounds with common scaffolds generated by the SNG package. Significant enrichment was 
measured using a hypergeometric test. 
Pharmacophore generation 
The bioactive conformations of around 30 ligands (described in Supporting information.2 tables 
S16,S19 and S20) co-crystallized with the three target proteins served as input for 
pharmacophore identification using the PharmaGist software.
42
 Among the multiple 
pharmacophore schemes that were generated we choose the one closely resembling the known 
interactions of the ligands with the target proteins. 
Docking and scoring 
The CSAR-2014 Fxa.SYK and TrmD dataset provided by the organizers was subjected to 
multiple (50) conformation generation using the default settings of the FROG2 package.
43
 The 
docking was performed using the Pharmer software
44
 and the chemical pharmacophoric features 
derived using the PharmaGist software served as constrains to guide the placement of the ligands 
during docking. The protein backbone of the residues other than the interacting residues in the 
active site served as excluded volumes. These docked structures were subjected to SMINA 
optimization and scoring.  
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Figure 1. The proposed workflow used for docking and scoring the CSAR-2014 compounds.  
 
Figure 2. (a) The 2D interaction profile of ‘FXa_gtc000401_2.07.pdb’ active site with its co-










structure together with the ligand based pharmacophore that was used for docking CSAR-2014 
FXa ligands. (c) The 2D interaction profile of ‘gtc000224_SYK.pdb’ active site with its co-
crystal structure ‘GTC000224A’. (d) The 3D interaction diagram ‘gtc000224_SYK.pdb’ with its 
co-crystal structure ‘GTC000224A’ together with the ligand based pharmacophore that was used 
for docking CSAR-2014 SYK ligands. (e) The 2D interaction profile of ‘TRMD_448.pdb’ active 
site with its co-crystal structure ‘GTC000448A’. (f) The 3D interaction diagram 
‘TRMD_448.pdb’ with its co-crystal structure ‘GTC000448A’together with the ligand based 
pharmacophore that was used for docking CSAR-2014 TrmD ligands. 
 
 
Figure 3. (a) The 2D interaction profile of the predicted pose of ‘GTC000101’ with 
‘fxa_gtc000401_2.07.pdb’, (b) The 3D interaction diagram ‘FXa_gtc000401_2.07.pdb’ with its 
cognate co-crystal structure (in green) together the predicted pose of ‘GTC000101’, (c) The 2D 
interaction profile of the predicted pose of ‘GTC000224A’ with ‘gtc000224_SYK.pdb’, (d) The 









predicted pose of ‘GTC000224A’,  (e) The 2D interaction profile of the predicted pose of 
‘GTC000448A’ with ‘gtc000224_SYK.pdb’. (f) The 3D interaction diagram ‘TrmD_448.pdb’ 
with its co-crystallized (in green) and the predicted pose of ‘GTC000448A’.  
  
Figure 4. The ROC curves for FXa, SYK and TrmD depecting the prediction quality of the 




Table 1. The motifs/binding sites, residues that constitute these motifs/binding sites and their 
structural integrity status in the CSAR-2014 FXa crystal structure ‘FXa_gtc000401_2.07.pdb’. 
motif/binding site Residues FXa_gtc000401_2.07.pdb 
Catalytic triad Asp102,His57 & Ser195 Intact 
S4 Phe174,Glu97,Tyr99,Trp215 
Partially intact, but Glu97 is pointing 
away 
Aromatic Box Phe174,Tyr99,Trp215 intact 
Catation hole 
Backbone carbonyl & sidechain of 
glu97 Not present 
S1 Gly219,Asp189,Tyr228 & Gln 192 
Partially intact, but Gln192 is pointing 
away 
Disulphide bridge 
1 Cys191-Cys220 Intact 
Disulphide 
bruidge 2 Cys58-Cys42 Intact 
Autolysis loop Arg143-Arg154 Intact 
Overall structure 2 beta barrels + 3 alpha helicies Intact 
 
  
Table 2. The motifs/binding sites, residues that constitute these motifs/binding sites and their 
structural integrity status in 3FQE, “SYK_GTC000224.pdb” and “SYK_GTC000249.pdb”. 




Hinge binding pocket Ala451 ,Met450 Intact Intact  Intact 




hydrophobic pocket 1 
(left of hinge) 
 Glu452,Gly454,Leu3
77 
Intact  Intact  Intact 
hydrophobic pocket 2 
(right of hinge) 
 Met448,Val433,Glu4
49 
Intact  Intact  Intact 
phosphorylation site 
(autocatalysis) 
Tyr525 Intact  Intact  Intact 
DFG motif  Asp512-Gly514 Intact  Not intact  Not intact 





p-loop  Gly378-Thr384 Intact  missing  Intact 




allosteric site  - -     
C-alpha helix  Pro411-Gln425 Intact  Intact  Intact 
  
  
Table 3. The motifs/binding sites, residues that constitute these motifs/binding sites in 1P9P 
and the major mutagenesis experiments. 
TrmD motif/binding 
site/structural element residues 
Major mutagenesis experiments within 
these motifs 
Active site/ B4 Leu85-Gln91 
 G91 → A: Loss of activity; no effect on 
tRNA binding.  
Active site/SpoU Gly113-Gly117 
 R114 → A: Loss of activity 
Y115 → A: Increases Km for S-adenosyl-
L-methionine 24-fold. 
G117 → A: Loss of activity. 
Active site/Adenine Ser131-Gly140 
 D135 → A: Loss of activity; no effect on 
tRNA binding.  
Y136 → A: Increases Km for S-adenosyl-
L-methionine 68-fold.  
Riobose binding pocket 
Leu87,Tyr86,Arg114,G
ly117,Ser88 R114 → A: Loss of activity. 
Salt-bridge Arg220-Asp135 
 D135 → A: Loss of activity; no effect on 
tRNA binding.  
Salt-bridge Arg114-Glu142  R114 → A: Loss of activity. 
Salt-bridge Arg121-Asp119   
G37-Adinine binding site 
Glu116,Asp169,Arg15
4   
 
  
Table 4. Overview of our pose prediction performance using CSARdock 2014 benchmark 




number of  
ligands 
docked 





















FXa 163 3 6.03  6.03  2.94 2.98 
SYK 276 8 4.28 4.01  2.58 2.46 
TrmD 31 14 3.20 2.53  3.84 3.52 
 
  
Table 5. Correlation between experimental activities and our scoring using CSARdock 2014 






















           
fxa_gtc000401
_2.07 163 0.001 
0.028 (0.181 to -
0.127) 
0.067 (0.218 to -
0.088) 
0.045 (0.148 to -
0.059) 
gtc000224_SY
K 276 0.013 
-0.112 (0.007 to -
0.228) 
-0.186 (-0.068 to 
-0.299) 
-0.122 (-0.043 to 
-0.200) 
gtc000249_SY
K 276 0.002 
0.046 (0.164 to -
0.074) 
0.218 (0.329 to 
0.100) 
0.15 (0.228 to 
0.072) 
TrmD_ 445 31 0.045 
-0.211 (0.155 to -
0.526) 
0.225 (0.540 to -
0.145) 
0.177 (0.417 to -
0.064) 
TrmD_ 447 31 0.006 
-0.077 (0.285 to -
0.420) 
-0.11 (0.255 to -
0.448) 
-0.063 (0.184 to -
0.310) 
TrmD_ 448 31 0.001 
-0.031 (0.327 to -
0.381) 
-0.273 (0.096 to -
0.577) 
-0.159 (0.083 to -
0.401) 
TrmD_ 452 31 0.000 
0.005 (0.359 to -
0.350) 
0.317 (0.609 to -
0.051) 
0.238 (0.472 to 
0.003) 
TrmD_453 31 0.164 
-0.406 (-0.060 to 
-0.664) 
0.152 (0.482 to -
0.216) 
0.098 (0.344 to -
0.148) 
TrmD_456 31 0.043 
-0.207 (0.159 to -
0.523) 
-0.248 (0.122 to -
0.558) 
-0.159 (0.083 to -
0.401) 
TrmD_459 31 0.041 
-0.202 (0.164 to -
0.519) 
0.202 (0.522 to -
0.168) 
0.181 (0.421 to -
0.059) 
TrmD_460 31 0.015 
-0.122 (0.243 to -
0.456) 
0.251 (0.560 to -
0.119) 
0.185 (0.425 to -
0.054) 
TrmD_464 31 0.133 
-0.365 (-0.013 to 
-0.637) 
0.117 (0.454 to -
0.249) 
0.076 (0.323 to -
0.170) 
TrmD_465 31 0.049 
-0.221 (0.145 to -
0.533) 
-0.4 (-0.039 to -
0.669) 
-0.233 (0.001 to -
0.468) 
a 
95% confidence interval in parentheses. 
  




















fxa_gtc000401_2.07_orange - (49,0) 0.65 (48,1) 0.55 (39,10) 0.58 (26,13) 
fxa_gtc000401_2.07_brown4 - (2,0) 1 (1,1) 1 (1,1) - (0,2) 
fxa_gtc000401_2.07_tan 0.62 (31,12) 0.65 (12,31) 0.68 (6,37) 0.7 (5,38) 
fxa_gtc000401_2.07_linen 0.75 (2,6) 0.75 (2,6) 0.75 (2,6) -(0,6) 
fxa_gtc000401_2.07_darkorchid4 -(4,0) -(4,0) -(4,0) -(4,0) 
fxa_gtc000401_2.07_paleturquoise
3 - (0,6) - (0,6) -(0,6) -(0,6) 
fxa_gtc000401_2.07_coral2 -(22,0) -(22,0) -(22,0) 0.57 (21,1) 
fxa_gtc000401_2.07_coral3 -(17,0) -(17,0) 0.21 (11,6) 0.53 (5,12) 
fxa_gtc000401_2.07_deeppink 0 (10,1) 0.63 (8,3) 0.63 (5,6) 0.18 (4,7) 
fxa_gtc000401_2.07_goldenrod3 .0(3,0) .0(3,0) .0(3,0) .0(3,0) 









gtc000224_SYK_brown 0.47 (98,9) 0.42 (69,29) 0.45 (34,64) 0.41 (11,87) 
gtc000224_SYK_royalblue 0.27 (10,3) 0.33 (3,10) 0.17 (1,12) 0.17 (1,12) 
gtc000224_SYK_blue 













gtc000249_SYK_brown 0.27 (98,9) 0.29(69,29) 0.38 (34,64) 0.43 (11,87) 
gtc000249_SYK_royalblue 0.4 (10,3) 0.30 (3,10) 0.17 (1,12) 0.17 (1,12) 
gtc000249_SYK_blue 





The number of active and nonactive ligands at the cut-off are given in parentheses. 
b
 Cut-off is 
an adjustable parameter for (9-pIC50) values based on which actives and inactives are defined 
 
  
Table 7. AUC Values Derived from ROC Curves for All Ligands and Clusters of TrmD docked 














TrmD_ 445_all 0.52 (18,13) 0.56 (12,19) 0.55 (5,26) 0.76 (2,29) 0.76 (2,29) 
TrmD_ 445 _lightpink3 0.64 (11,4) 0.55 (7,8) 0.27 (2,13) -(0,15) -(0,15) 
TrmD_ 445 _orangered1 -(0,2) -(0,2) -(0,2) -(0,2) -(0,2) 
TrmD_ 445 _grey 0.18 (4,7) 0.28 (2,9) -(0,11) -(0,11) -(0,11) 
TrmD_ 445 _chartreuse3 -(3,0) -(3,0) -(3,0) 0.5 (2,1) 0.5 (2,1) 
TrmD_ 447_all 0.69 (18,13) 0.56 (12,19) 0.45 (5,26) 0.62 (2,29) 0.62 (2,29) 
TrmD_ 447 _lightpink3 0.7 (11,4) 0.41 (7,8) 0.31 (2,13) -(0,15) -(0,15) 
TrmD_ 447 _orangered1 -(0,2) -(0,2) -(0,2) -(0,2) -(0,2) 
TrmD_ 447 _grey 0.54 (4,7) 0.56 (2,9) -(0,11) -(0,11) -(0,11) 
TrmD_ 447 _chartreuse3 -(3,0) -(3,0) -(3,0) 1 (2,1) 1 (2,1) 
TrmD_ 448_all 0.69 (18,13) 0.56 (12,19) 0.45 (5,26) 0.62 (2,29) 0.62 (2,29) 
TrmD_ 448 _lightpink3 0.71 (11,4) 0.41 (7,8) 0.31 (2,13) -(0,15) -(0,15) 
TrmD_ 448 _orangered1 -(0,2) -(0,2) -(0,2) -(0,2) -(0,2) 
TrmD_ 448 _grey 0.54 (4,7) 0.56 (2,9) -(0,11) -(0,11) -(0,11) 
TrmD_ 448 _chartreuse3 -(3,0) -(3,0) -(3,0) 1 (2,1) 1 (2,1) 
TrmD_ 452_all 0.21 (18,13) 0.21 (12,19) 0.61 (5,26) 0.90 (2,29) 0.90 (2,29) 
TrmD_ 452 _lightpink3 0.18 (11,4) 0.57 (7,8) 0.35 (2,13) -(0,15) -(0,15) 
TrmD_ 452 _orangered1 -(0,2) -(0,2) -(0,2) -(0,2) -(0,2) 
TrmD_ 452 _grey 0 (4,7) 0.07 (2,9) -(0,11) -(0,11) -(0,11) 
TrmD_ 452 _chartreuse3 -(3,0) -(3,0) -(3,0) 0.5 (2,1) 0.5 (2,1) 
TrmD_453_all 0.36 (18,13) 0.41 (12,19) 0.69 (5,26) 0.97 (2,29) 0.97 (2,29) 
TrmD_453_lightpink3 0.25 (11,4) 0.48 (7,8) 0.54 (2,13) -(0,15) -(0,15) 
TrmD_453_orangered1 -(0,2) -(0,2) -(0,2) -(0,2) -(0,2) 
TrmD_453_grey 0.36 (4,7) 0 (2,9) -(0,11) -(0,11) -(0,11) 
TrmD_453_chartreuse3 -(3,0) -(3,0) -(3,0) 1 (2,1) 1 (2,1) 
TrmD_456_all 0.59 (18,13) 0.64 (12,19) 0.64 (5,26) 0.60 (2,29) 0.60 (2,29) 
TrmD_456_lightpink3 0.59 (11,4) 0.64 (7,8) 0.54 (2,13) -(0,15) -(0,15) 
TrmD_456_orangered1 -(0,2) -(0,2) -(0,2) -(0,2) -(0,2) 
TrmD_456_grey 0.43 (4,7) 0.33 (2,9) -(0,11) -(0,11) -(0,11) 
TrmD_456_chartreuse3 -(3,0) -(3,0) -(3,0) 1 (2,1) 1 (2,1) 
TrmD_459_all 0.29 (18,13) 0.44 (12,19) 0.63 (5,26) 0.86 (2,29) 0.86 (2,29) 
TrmD_459_lightpink3 0.16 (11,4) 0.43 (7,8) 0.38 (2,13) -(0,15) -(0,15) 
TrmD_459_orangered1 -(0,2) -(0,2) -(0,2) -(0,2) -(0,2) 
TrmD_459_grey 0.21 (4,7) 0.06 (2,9) -(0,11) -(0,11) -(0,11) 
TrmD_459_chartreuse3 -(3,0) -(3,0) -(3,0) 0 (2,1) 0 (2,1) 
TrmD_460_all 0.39 (18,13) 0.34 (12,19) 0.6 (5,26) 0.88 (2,29) 0.88 (2,29) 
TrmD_460_lightpink3 0.61 (11,4) 0.34 0.35 (2,13) -(0,15) -(0,15) 
TrmD_460_orangered1 -(0,2) -(0,2) -(0,2) -(0,2) -(0,2) 
TrmD_460_grey 0.18 (4,7) 0 (2,9) -(0,11) -(0,11) -(0,11) 
TrmD_460_chartreuse3 -(3,0) -(3,0) -(3,0) 0.5 (2,1) 0.5 (2,1) 
TrmD_464_all 0.38 (18,13) 0.51 (12,19) 0.55 (5,26) 0.97 (2,29) 0.97 (2,29) 
TrmD_464_lightpink3 0.34 (11,4) 0.64 (7,8) 0.35 (2,13) -(0,15) -(0,15) 
TrmD_464_orangered1 -(0,2) -(0,2) -(0,2) -(0,2) -(0,2) 
TrmD_464_grey 0.39 (4,7) 0.17 -(0,11) -(0,11) -(0,11) 
TrmD_464_chartreuse3 -(3,0) -(3,0) -(3,0) 1 (2,1) 1 (2,1) 
TrmD_465_all 0.68 (18,13) 0.75 (12,19) 0.58 (5,26) 0.48 (2,29) 0.48 (2,29) 
TrmD_465_lightpink3 0.43 (11,4) 0.61 (7,8) 0.69(2,13) -(0,15) -(0,15) 
TrmD_465_orangered1 -(0,2) -(0,2) -(0,2) -(0,2) -(0,2) 
TrmD_465_grey 0.68 (4,7) 1 (2,9) -(0,11) -(0,11) -(0,11) 
TrmD_465_chartreuse3 -(3,0) -(3,0) -(3,0) 1 (2,1) 1 (2,1) 
a. The number of active and nonactive ligands at the cut-off is given in parentheses.b Cut-off is 
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